Business Of Biotech cover image

Business Of Biotech

The Peptide Promise With NervGen's Mike Kelly

Oct 7, 2024
Mike Kelly, CEO of NervGen, leads the charge in peptide therapeutics aimed at repairing the central nervous system. He shares his transformation from a sales background to a biotech leader, emphasizing the importance of mentorship in understanding complex biopharma science. The discussion highlights NervGen's innovative strategies for tackling neurodegenerative diseases and the challenges of peptide manufacturing. Kelly also reflects on navigating startup dynamics, funding strategies, and the significance of collaboration in biopharma success.
59:19

Episode guests

Podcast summary created with Snipd AI

Quick takeaways

  • Mike Kelly's shift from sales to CEO at NervGen exemplifies the importance of integrating business acumen with scientific knowledge in life sciences.
  • NerveGen's focus on peptide therapeutics highlights their potential to bridge traditional small and large molecule therapies, particularly in treating neurological conditions.

Deep dives

NerveGen's Mission and Peptide Development

NerveGen aims to enhance the nervous system's ability to repair itself following traumatic injury or disease, specifically through the use of therapeutic peptides. The company's lead peptide is currently undergoing clinical trials targeting spinal cord injury, with plans to expand into conditions such as stroke, Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis. Peptides are regarded as a unique treatment modality due to their ability to be effective in ways that are not entirely understood, often bridging the gap between traditional small and large molecule therapies. Their increased vascular permeability and bioavailability present potential advantages when addressing neurological conditions.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner